The incidence of lymphoma and myeloma is increased in rheumatoid arthritis (RA) 
A relation between rheumatoid arthritis (RA) and myeloma was proposed by Galli and Chiti in 19551 and supported by Goldenberg et al. 2 Firm evidence that RA is associated with an excess risk of both myeloma and lymphoma was first obtained from a large population study in Finland in 1982.3 Confirmation of the increased risks of myeloma and lymphoma in RA have recently been obtained from smaller studies with clearer diagnostic criteria. 4 5 There is evidence that the risk of these malignancies relates to the duration of RA,6 but there is little published information on other risk factors. In particular, the possible relevance of monoclonal gammopathy to malignancy in rheumatic disease has only recently been discussed.7 8 In this longitudinal study of patients with paraproteinaemia we attempted to evaluate the risk of lymphoproliferative malignancy and relate it to a variety of easily measured parameters.
Patients and methods
We identified 23 patients with RA9 and a serum monoclonal or biclonal paraprotein who had attended a district rheumatology unit serving a population of 800 000 over an eight year period. Their giving an overall prevalence of 1-3%. In two large series a total of eight cases of monoclonal gammopathy were found among 640 patients with seropositive RA,2' giving a prevalence of 125%. As both RA and paraproteinaemia occur in about 1% of the population the association between the two conditions at best seems to be slight. The significance of monoclonal gammopathy in RA differs from that in the normal population, however. We suggest that the development of lymphoproliferative disorders in some patients with RA may be predicted by the presence of monoclonal paraprotein which, although not found in gross excess in a rheumatoid population, seems to carry a much higher risk of malignant transformation in patients with RA than in the population at large. The increased risk of lymphoma and myeloma in RA may be due to chronic immune stimulation and the associated B lymphocyte activation,28 and rheumatoid lymph nodes are known to be a major site of this B cell driven activity.29
The class of paraprotein present may be of some prognostic value. Previous studies have reported more IgA and less IgG paraproteins in patients with RA than found in the general population.21 22 30 Our findings are similar, and suggest that the risk of myeloma may be greater in those patients with a monoclonal IgAk paraprotein. The x:k light chain ratio in our patients with an IgA paraprotein was 0-2, which contrasts with the ratio of 13 reported in a large series of patients with monoclonal gammopathy without RA. 30 The reported x:k ratios in the other paraprotein types were similar to those found in our study. Other well recognised factors, such as a high concentration of paraprotein and the presence of immune paresis, were also predictive of malignancy in our patients.
The presence of urinary free light chains has been proposed as a marker of malignancy in patients with primary Sjogren's syndrome.3' 32 We were unable to show a relation between free light chain excretion and malignant transformation in our patients with secondary Sj6gren's syndrome. Both our patients who developed lymphoma had associated secondary Sjogren's syndrome, however, and the increased risk of lymphoma in Sjogren's syndrome is unaffected by the presence of associated connective tissue disease.20 Amyloidosis may also complicate longstanding RA and can be associated with the production of paraprotein. No evidence of amyloid was found in any of our patients, though it was not actively sought unless felt to be of potential clinical relevance.
Bone marrow examinations were abnormal in over half our patients. Abnormality can be difficult to define in patients with RA as a reactive plasmacytosis is commonly associated with active joint disease, but was based more on atypical morphology and distribution of plasma cells than on their numbers alone. Certain features, such as focal aggregation or paratrabecular distribution of plasma cells, suggest the development of malignancy,33 but strict criteria for the diagnosis of myeloma were met in only five patients during the follow up period.'0 The bone marrow was abnormal in both patients who later developed lymphoma. Six patients with excessive or abnormal plasma cells have not developed lymphoproliferative disease, and this group includes both patients with biclonal gammopathy. One patient with an IgG paraprotein has now developed immune paresis, however, and another with an IgM paraprotein has findings suggestive of early Waldenstrom's macroglobulinaemia, so clearly this borderline group remains a cause for concern and later progression to lymphoprolferative malignancy remains a strong possibility.
Only eight patients had received treatment with second line agents or oral steroids, and there is no evidence that these drugs predispose to malignancy. One other patient had received cytotoxic drugs. There is growing concern that the use of such agents in patients with severe RA may increase the risk of later lymphoma,3M though this patient has remained well. A single death has occurred among our seven patients with lymphoproliferative disease, but it is too early to speculate on the long term prognosis.
Our study offers evidence that the development of paraproteinaemia in patients with RA is related more to disease severity than to duration. The median age of our group when a paraprotein was first detected was 58 years and the average duration of RA at this stage was six years, while most of our patients had erosive disease and were seropositive. We suggest that paraproteinaemia occurring in patients with RA should be prompdy investigated with a skeletal survey and a bone marrow examination. Elderly men with severe disease are most at risk of developing a lymphoproliferative disorder, and the presence of an IgAM paraprotein may indicate a special risk of myeloma. All patients with morphological abnormalities on bone marrow emination should be followed up six months later with paraprotein measurement and immunoglobulin estimation. A rise of 5 g/l in paraprotein concentration over one year or the development of immune paresis should prompt reinvestigation as the response to treatment of lymphoproliferative disease seems to be at least as good as that obtained in patients without RA. in rheumatoid arthritis. 
Prognostic significance of paraproteinaemia

